Hypertension and the bradykinin system

Current Hypertension Reports

Volumn 11, Issue 3, 2009, Pages 178-181

  Sharma, Jagdish N ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; APROTININ; B 5630; B 9972; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ RECEPTOR; BRADYKININ RECEPTOR AGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KALLIKREIN; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PARVOVIRUS VECTOR; PROSTACYCLIN; PROSTAGLANDIN; SODIUM; TISSUE KALLIKREIN; UNCLASSIFIED DRUG; WATER;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG MECHANISM; ESSENTIAL HYPERTENSION; FLUID BALANCE; GENE TARGETING; GENE TRANSFER; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY INJURY; MODULATION; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE DRUG DOSE; SODIUM BALANCE; VASOCONSTRICTION; VASODILATATION; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ANIMALS; BLOOD PRESSURE; BRADYKININ; HUMANS; HYPERTENSION; MICROCIRCULATION; VASOCONSTRICTION;

EID: 65749105942     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0032-7     Document Type: Review

References (16)

1. Sharma JN: Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system. Arch Med Res 2006, 37:299-306.
2. Katori M, Majima M: A missing link between a high salt intake and blood pressure increase. J Pharmacol Sci 2006, 100:370-390.
3. Leeb-Lundberg LMF, Marceau F, Müller-Esterl W, et al.: International union of Pharmacology. XLV. Classification of kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005, 57:27-77.
4. Sharma JN: The brRdykinin system: role in cardiovascular and diabetic pathophysiology. Curr Top Pharmacol 2007, 11:91-100.
5. Sharma JN, Al-Dhalmawi GS: Tradykinin receptor antagonists: therapeutic implications. IDrugs 2003, 6:581-586.
6. Chao J, Yin H, Gao L, et al.: Tissue kallikrein elicits cardioprotection by direct kinin B2 receptor activation independent of kinin formation. Hypertension 2008, 52:715-725.
7. Katori M, Majima M: The renalIkallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension. Crit Rev Clin Lab Sci 2003, 40:43-115.
8. Katori M, Majima M: Roles of the renal kallikrein-kinin system in salt-sensitive hypertension. Hypertension 2004, 44:e12-e13.
9. Chao J, Chao L: Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol 2005, 90:291-298.
10. Zhao C, Wang P, Xiao X, et al.: Gene therapy with tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertension in rats. Hypertension 2003, 42:1026-1033.
11. Wang T, Li H, Zhao C, et al.: Recombinant adeno-associated virus-mediated kallikrein-gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 2004, 11:1342-1350.
12. Jaffa AA, DurazoAArvizu R, Zheng D, et al.: Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 2003, 52:1215-1221.
13. Sharma JN, Kesavarao U: Changes in plasma prekallikrein activity, blood pressure, and left ventricular thickness in hypertensive and normotensive diabetic rats. Methods Find Exp Clin Pharmacol 2007, 29:75-78.
14. Sharma JN, Kesavarao U: Effect of captopril on urinary kallikrein, blood pressure and myocardial hypertrophy in diabetic spontaneously hypertensive rats. Pharmacology 2002, 64:196-200.
15. Madeddu P, EmanueTi C, El-Dahr S: Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol 2007, 3:208-221.
16. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, et al.: Treatment of severe pulmonary hypertension: A bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 2005, 26:1292-1300.